Full Text | PDF

Theranostics 2015; 5(9):985-994. doi:10.7150/thno.11938 This issue Cite

Research Paper

DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition

Xiaoqiu Wu^1*, Zilong Zhao^1*, Huarong Bai¹, Ting Fu^{1, 2}, Chao Yang^{1, 3}, Xiaoxiao Hu¹, Qiaoling Liu¹, Carole Champanhac², I-Ting Teng², Mao Ye^1✉, Weihong Tan^{1, 2✉}

1. Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha 410082, China
2. Departments of Chemistry, Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Shands Cancer Center, University of Florida Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL 32611-7200, USA
3. College of Life and Environmental Science, National Navel Orange Engineering Research Center, Gannan Normal University, Economic & Technological Development Zone, Ganzhou 341000, China
* Xiaoqiu Wu and Zilong Zhao contributed equally.

✉ Corresponding authors: Prof. Weihong Tan, E-mail: tanufl.edu; Prof. Mao Ye, E-mail: yemaocsucom

Abstract

In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC). Aptamer XQ-2d selectively binds to PL45 cells with a dissociation constant in the nanomolar range, as determined by its recognition of PL45 tumor cells in mice. Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%). Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

Keywords: aptamer, cell-SELEX, pancreatic ductal adenocarcinoma, molecular probe

Citation styles

©2024 Ivyspring International Publisher. Terms of use